JN 303
Alternative Names: JN-303; KB-303Latest Information Update: 06 Apr 2023
Price :
$50 *
At a glance
- Originator Krystal Biotech
- Developer Jeune; Krystal Biotech
- Class Gene therapies; Skin disorder therapies
- Mechanism of Action Extracellular matrix protein replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Skin disorders
Most Recent Events
- 06 Apr 2023 Phase-I clinical trials in Skin disorders in USA (Parenteral), before April 2023
- 25 Mar 2022 Preclinical trials in Skin disorders in USA (Parenteral) before March 2022 (Jeune pipeline, March 2022)
- 31 Dec 2021 Krystal Biotech has patents protection for STAR-D platform in USA before December 2021